RT Journal Article
T1 Sclerostin serum levels in patients with systemic autoimmune diseases.
A1 Fernández-Roldán, Concepción
A1 Genre, Fernanda
A1 López-Mejías, Raquel
A1 Ubilla, Begoña
A1 Mijares, Verónica
A1 Cano, Daniel Sánchez
A1 Robles, Concepción López
A1 Callejas-Rubio, José Luis
A1 Fernández, Raquel Ríos
A1 Ruiz, Manuela Expósito
A1 González-Gay, Miguel Á
A1 Ortego Centeno, Norberto
AB Systemic autoimmune diseases (SADs) are associated with lower bone mass and an increased risk of fractures. Sclerostin has a pivotal role in bone metabolism. Available data on circulating sclerostin levels in healthy subjects are limited, whereas those in SAD patients are absent. Our objective was to determine circulating sclerostin concentrations in systemic lupus erythematosus (SLE), systemic sclerosis (SSc) and Crohn's disease (CD) patients, and to analyze the factors associated with sclerostin concentrations. In this cross-sectional case-control study, serum sclerostin levels were measured in 38 SLE patients, 20 CD patients, 8 SSc patients and 20 healthy controls using a sclerostin ELISA. The mean values of the sclerostin (95% confidence interval) were 35.36 pmol l(-1) (12-101) in patients and 33.92 pmol l(-1) (2.31-100) in control subjects. The mean sclerostin value was 36.4 pmol l(-1) (22.1-48.5) in SLE patients, 26.7 pmol l(-1) (17.3-36.3) in CD patients and 51.8 pmol l(-1) (26.5-77.1) in SSc patients (P=0.001). Serum sclerostin levels were positively correlated with age (P
SN 2047-6396
YR 2016
FD 2016-02-03
LK https://hdl.handle.net/10668/25108
UL https://hdl.handle.net/10668/25108
LA en
DS RISalud
RD Apr 11, 2025